Symbio and OmniComm expand on current partnership, sign five-year contract

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/undefined undefined)
(Image: Getty/undefined undefined)

Related tags: Contract, Partnership, Clinical trial, Clinical trial management, Data management

Symbio signs five-year contract with clinical data management technology company OmniComm Systems to develop and manage clinical study databases.

The New York-based contract research organization (CRO) will use OmniComm’s TrialMaster​ version 5 for the development and management of its clinical trials as part of the five-year agreement.

A spokesperson for Symbio told us that the company has been working with OmniComm​ for several years. Through the companies’ existing partnership, Symbio has been responsible for electronic case report form (eCRF) design, edit check specification, data cleaning, training and locking procedures.

“Basically, OmniComm has done the technology portion while Symbio has been doing the clinical data management portion. With this agreement now in place, Symbio is able to build, deploy, and update the clinical study database directly in the TrialMaster system without having to go through OmniComm to do so,”​ the spokesperson explained.

With this agreement in place, Symbio can get to a go-live state and implement post-production changes quicker than it could previously since it does not have a third party to schedule with, enabling the company to be more cost efficient, the spokesperson said

“The investigational research sites appreciate a consistent theme and workflow from study to study, as do our sponsors. This greatly reduces training, errors, and frustration for everyone,” ​they added.

In 2018, Symbio launched its European operations to support clients with global trial and stated that OmniComm’s presence in Europe was a major factor in the selection of using TrialMaster.  


Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more